Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Rqbio Covid Limited has 1 pending office action in Biotechnology & Pharmaceuticals. The matter is assigned to 1 distinct examiner in 1 distinct art unit. OUSPENSKI, ILIA I is the busiest examiner, with 1 pending matter, so the available prosecution data reflects a single examination channel.
This structure supports a focused response plan centered on the pending action, the assigned examiner, and the relevant biotechnology or pharmaceutical disclosure. Counsel can prepare a targeted claim and specification review rather than coordinating positions across multiple art units. Any examiner interview or amendment should address the complete unresolved record while preserving support for the intended technical scope.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Double-patenting + other | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| OUSPENSKI, ILIA I | 1 | 77.3% | +20.6% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18709419 | COMPOSITIONS | OUSPENSKI, ILIA I | — |
| Art Unit | Apps |
|---|---|
| 1644 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18709419 | COMPOSITIONS | OUSPENSKI, ILIA I | 1644 | §102§112DP | Non-Final OA | — | Pending | May 10, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialRqbio Covid Limited has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Ilia I Ouspenski has the most, with 1 of Rqbio Covid Limited's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
